Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoB

Line Engelbrechtsen; J Lundgren; Nicolai Jacob Wewer Albrechtsen; Yuvaraj  Mahendran; Eva Pers Winning Iepsen; P. Finocchietto; Anna Elisabet  Jonsson; Sten Madsbad; Jens Juul Holst; Henrik Vestergaard; T. Hansen; Signe Sørensen Torekov

doi:10.1002/osp4.133

Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoB

Line Engelbrechtsen, J Lundgren, Nicolai Jacob Wewer Albrechtsen, Yuvaraj Mahendran, Eva Pers Winning Iepsen, P. Finocchietto, Anna Elisabet Jonsson, Sten Madsbad, Jens Juul Holst, Henrik Vestergaard, T. Hansen, Signe Sørensen Torekov

7 Citations (Scopus)

146 Downloads (Pure)

Abstract

Background: Dislipidaemia and increased levels of apolipoprotein B (apoB) in individuals with obesity are risk factors for development of cardiovascular disease (CVD). The aim of this study was to investigate the effect of weight loss and weight maintenance with and without liraglutide treatment on plasma lipid profiles and apoB.

Methods: Fifty-eight individuals with obesity (body mass index 34.5 ± 3.0 kg/m2 [mean ± SD]) were included in this study. After 8 weeks on a very low-calorie diet (800 kcal/day), participants were randomized to weight maintenance with meal replacements with or without liraglutide (1.2 mg daily) for 1 year. Plasma samples from before and after weight loss and after 1 year of weight maintenance were subjected to nuclear magnetic resonance-based lipidomics analysis.

Results: After an 8-week low-calorie diet, study participants lost 12.0 ± 2.9 kg (mean ± SD) of their body weight, which was reflected in their lipid profiles (80 out of 124 lipids changed significantly), including reduced levels of apoB, total cholesterol, free cholesterol, remnant cholesterol, triglycerides, low-density lipoprotein and very low-density lipoprotein subclasses. After 1 year of maintained weight loss, the majority of the lipids had returned to pre-weight loss levels even though weight loss was successfully maintained in both groups. Interestingly, apoB levels remained low in the liraglutide treated group (apoB change: 0.03 ± 0.02 mmol/L, p = 0.4) in contrast to an increase in the control group (apoB change: 0.06 ± 0.07 mmol/L, p = 0.02).

Conclusion: An 8-week low-calorie diet, in individuals with obesity, reduced plasma levels of lipids and the atherogenic marker apoB. After 1 year of weight maintenance, only study participants treated with liraglutide maintained reduced levels of apoB, despite similar body weight maintenance. Treatment with liraglutide may therefore reduce apoB levels and thus reflect lower CVD risk. Including apoB measurements in clinical practice when monitoring patients with dislipidemia or CVD might prove to be useful.

Original language	English
Journal	Obesity Science & Practice
Volume	3
Issue number	4
Pages (from-to)	425-433
Number of pages	9
ISSN	2055-2238
DOIs	https://doi.org/10.1002/osp4.133
Publication status	Published - Dec 2017

Keywords

Journal Article

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/osp4.133Licence: CC BY

Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoBFinal published version, 339 KBLicence: CC BY
Engelbrechtsen_et_al-2017-Obesity_Science_&_PracticeFinal published version, 339 KB

Cite this

Engelbrechtsen, L., Lundgren, J., Wewer Albrechtsen, N. J., Mahendran, Y., Iepsen, E. P. W., Finocchietto, P., Jonsson, A. E., Madsbad, S., Holst, J. J., Vestergaard, H., Hansen, T., & Torekov, S. S. (2017). Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoB. Obesity Science & Practice, 3(4), 425-433. https://doi.org/10.1002/osp4.133

@article{e3e7d45b9c5245a8a4d722a59392313e,

title = "Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoB",

abstract = "Background: Dislipidaemia and increased levels of apolipoprotein B (apoB) in individuals with obesity are risk factors for development of cardiovascular disease (CVD). The aim of this study was to investigate the effect of weight loss and weight maintenance with and without liraglutide treatment on plasma lipid profiles and apoB.Methods: Fifty-eight individuals with obesity (body mass index 34.5 ± 3.0 kg/m2 [mean ± SD]) were included in this study. After 8 weeks on a very low-calorie diet (800 kcal/day), participants were randomized to weight maintenance with meal replacements with or without liraglutide (1.2 mg daily) for 1 year. Plasma samples from before and after weight loss and after 1 year of weight maintenance were subjected to nuclear magnetic resonance-based lipidomics analysis.Results: After an 8-week low-calorie diet, study participants lost 12.0 ± 2.9 kg (mean ± SD) of their body weight, which was reflected in their lipid profiles (80 out of 124 lipids changed significantly), including reduced levels of apoB, total cholesterol, free cholesterol, remnant cholesterol, triglycerides, low-density lipoprotein and very low-density lipoprotein subclasses. After 1 year of maintained weight loss, the majority of the lipids had returned to pre-weight loss levels even though weight loss was successfully maintained in both groups. Interestingly, apoB levels remained low in the liraglutide treated group (apoB change: 0.03 ± 0.02 mmol/L, p = 0.4) in contrast to an increase in the control group (apoB change: 0.06 ± 0.07 mmol/L, p = 0.02).Conclusion: An 8-week low-calorie diet, in individuals with obesity, reduced plasma levels of lipids and the atherogenic marker apoB. After 1 year of weight maintenance, only study participants treated with liraglutide maintained reduced levels of apoB, despite similar body weight maintenance. Treatment with liraglutide may therefore reduce apoB levels and thus reflect lower CVD risk. Including apoB measurements in clinical practice when monitoring patients with dislipidemia or CVD might prove to be useful.",

keywords = "Journal Article",

author = "Line Engelbrechtsen and J Lundgren and {Wewer Albrechtsen}, {Nicolai Jacob} and Yuvaraj Mahendran and Iepsen, {Eva Pers Winning} and P. Finocchietto and Jonsson, {Anna Elisabet} and Sten Madsbad and Holst, {Jens Juul} and Henrik Vestergaard and T. Hansen and Torekov, {Signe S{\o}rensen}",

year = "2017",

month = dec,

doi = "10.1002/osp4.133",

language = "English",

volume = "3",

pages = "425--433",

journal = "Obesity Science & Practice",

issn = "2055-2238",

publisher = "JohnWiley & Sons, Inc.",

number = "4",

}

TY - JOUR

T1 - Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoB

AU - Engelbrechtsen, Line

AU - Lundgren, J

AU - Wewer Albrechtsen, Nicolai Jacob

AU - Mahendran, Yuvaraj

AU - Iepsen, Eva Pers Winning

AU - Finocchietto, P.

AU - Jonsson, Anna Elisabet

AU - Madsbad, Sten

AU - Holst, Jens Juul

AU - Vestergaard, Henrik

AU - Hansen, T.

AU - Torekov, Signe Sørensen

PY - 2017/12

Y1 - 2017/12

N2 - Background: Dislipidaemia and increased levels of apolipoprotein B (apoB) in individuals with obesity are risk factors for development of cardiovascular disease (CVD). The aim of this study was to investigate the effect of weight loss and weight maintenance with and without liraglutide treatment on plasma lipid profiles and apoB.Methods: Fifty-eight individuals with obesity (body mass index 34.5 ± 3.0 kg/m2 [mean ± SD]) were included in this study. After 8 weeks on a very low-calorie diet (800 kcal/day), participants were randomized to weight maintenance with meal replacements with or without liraglutide (1.2 mg daily) for 1 year. Plasma samples from before and after weight loss and after 1 year of weight maintenance were subjected to nuclear magnetic resonance-based lipidomics analysis.Results: After an 8-week low-calorie diet, study participants lost 12.0 ± 2.9 kg (mean ± SD) of their body weight, which was reflected in their lipid profiles (80 out of 124 lipids changed significantly), including reduced levels of apoB, total cholesterol, free cholesterol, remnant cholesterol, triglycerides, low-density lipoprotein and very low-density lipoprotein subclasses. After 1 year of maintained weight loss, the majority of the lipids had returned to pre-weight loss levels even though weight loss was successfully maintained in both groups. Interestingly, apoB levels remained low in the liraglutide treated group (apoB change: 0.03 ± 0.02 mmol/L, p = 0.4) in contrast to an increase in the control group (apoB change: 0.06 ± 0.07 mmol/L, p = 0.02).Conclusion: An 8-week low-calorie diet, in individuals with obesity, reduced plasma levels of lipids and the atherogenic marker apoB. After 1 year of weight maintenance, only study participants treated with liraglutide maintained reduced levels of apoB, despite similar body weight maintenance. Treatment with liraglutide may therefore reduce apoB levels and thus reflect lower CVD risk. Including apoB measurements in clinical practice when monitoring patients with dislipidemia or CVD might prove to be useful.

AB - Background: Dislipidaemia and increased levels of apolipoprotein B (apoB) in individuals with obesity are risk factors for development of cardiovascular disease (CVD). The aim of this study was to investigate the effect of weight loss and weight maintenance with and without liraglutide treatment on plasma lipid profiles and apoB.Methods: Fifty-eight individuals with obesity (body mass index 34.5 ± 3.0 kg/m2 [mean ± SD]) were included in this study. After 8 weeks on a very low-calorie diet (800 kcal/day), participants were randomized to weight maintenance with meal replacements with or without liraglutide (1.2 mg daily) for 1 year. Plasma samples from before and after weight loss and after 1 year of weight maintenance were subjected to nuclear magnetic resonance-based lipidomics analysis.Results: After an 8-week low-calorie diet, study participants lost 12.0 ± 2.9 kg (mean ± SD) of their body weight, which was reflected in their lipid profiles (80 out of 124 lipids changed significantly), including reduced levels of apoB, total cholesterol, free cholesterol, remnant cholesterol, triglycerides, low-density lipoprotein and very low-density lipoprotein subclasses. After 1 year of maintained weight loss, the majority of the lipids had returned to pre-weight loss levels even though weight loss was successfully maintained in both groups. Interestingly, apoB levels remained low in the liraglutide treated group (apoB change: 0.03 ± 0.02 mmol/L, p = 0.4) in contrast to an increase in the control group (apoB change: 0.06 ± 0.07 mmol/L, p = 0.02).Conclusion: An 8-week low-calorie diet, in individuals with obesity, reduced plasma levels of lipids and the atherogenic marker apoB. After 1 year of weight maintenance, only study participants treated with liraglutide maintained reduced levels of apoB, despite similar body weight maintenance. Treatment with liraglutide may therefore reduce apoB levels and thus reflect lower CVD risk. Including apoB measurements in clinical practice when monitoring patients with dislipidemia or CVD might prove to be useful.

KW - Journal Article

U2 - 10.1002/osp4.133

DO - 10.1002/osp4.133

M3 - Journal article

C2 - 29259801

SN - 2055-2238

VL - 3

SP - 425

EP - 433

JO - Obesity Science & Practice

JF - Obesity Science & Practice

IS - 4

ER -

Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoB

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this